Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today ...

Susan Lois Hamilton, chair of the Department of Integrated Physiology, received her Ph.D. in biophysics from the University ...

The field of biotechnology has always transformed cutting-edge science into life-changing medicines, but today that transformation is happening at a staggering pace.

Many plants including cocoa, coffee and avocado cannot be gene-edited but a technique involving grafting could change that, ...

Researchers at Texas Tech University, led by Gunvant Patil, have developed a synthetic regeneration system that allows plants to regrow shoots directly from wounded tissue, eliminating the need for ...

The first agreement grants a license to a pioneering therapeutics company focused on developing a novel iPSC-based treatment for neurological disease. The partnership will leverage Pluristyx's ...

We have written about the promise of gene therapy to correct genetic disease many times. An exciting development happened ...

The MarketWatch News Department was not involved in the creation of this content.-- Third quarter revenue increased 15% year-over-year to $44.2 million -- Commercial Cell & Gene T ...

Details of the TN-201 clinical data presentation are as follows: ...

Third quarter total revenue of $160 million, Crysvita® revenue of $112 million and Dojolvi® revenue of $24 millionReaffirm 2025 Revenue Guidance: ...

Q3 2025 Earnings Call Transcript November 3, 2025 Krystal Biotech, Inc. beats earnings expectations. Reported EPS is $2.66, ...

Understanding how cells turn genes on and off is one of biology's most enduring mysteries. Now, a new technology developed by chemist Brian Liau and his collaborators at Harvard offers an ...